Tokushima University / Educator and Researcher Directory --- Kawada, Kei

Field of Study

○	ライフサイエンス, 医療薬学, 臨床薬理

Subject of Study

○	植物由来Exosome like nano-particleを利活用した新規抗神経炎症治療薬の開発 (植物由来Exosome like nano-particle, 臨床研究, トランスレーショナルリサーチ, 臨床薬理)

Book / Paper

Book:

1.	Kei Kawada : 血液がんの便秘重症化抑制-非刺激性下剤の使用促進で, 薬事日報, Tokyo, Oct. 2021.
2.	Kei Kawada : 薬剤師が実践すべき副作用へのロジカルアプローチ ~その症状，きちんと評価できていますか?~, 南江堂, Sep. 2021.
3.	Kei Kawada : 第52回ASHPミッドイヤー臨床薬学会議に参加して, Dec. 2018.

Academic Paper (Judged Full Paper):

1.	Kei Kawada, T Ishida, T Yoshioka, H Fukuda, T Hayashi, Mitsuhiro Goda and Keisuke Ishizawa : Association of non-steroidal anti-inflammatory drug use with encephalopathy development: An analysis using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) databases., Die Pharmazie, Vol.79, No.6, 118-123, 2024. (Summary) Encephalopathy is the most severe complication of various common infections, including influenza and herpes, and it often results in death or severe neurological disability. The risk factors for viral encephalopathy include non-steroidal anti-inflammatory drug (NSAID) use; however, studies on NSAID-related encephalopathy are limited. In this study, we aimed to investigate the characteristics of NSAID-related encephalopathy. We investigated the incidence of NSAID-related encephalopathy using data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) databases containing reports on spontaneous adverse effects (AEs) published by the Pharmaceuticals and Medical Devices Agency. We used these databases to detect AEs based on reported odds ratios. By separating suspicious drugs, concomitant drugs, and drug interactions involving NSAIDs, we investigated the relationship between encephalopathy pathology and AEs of NSAIDs. Significant encephalopathy signals were detected for loxoprofen and etodolac in the FAERS database and loxoprofen in the JADER database. In the JADER database, significant encephalopathy signals in loxoprofen-treated patients were detected in 70-79-year-old, 80-year-old, influenza viral infection, and herpes virus infection groups. Significant encephalopathy signals in patients with herpes virus infection were detected in the 80-year-old and loxoprofen-treated groups. Regarding the involvement of loxoprofen in the development of encephalopathy, the JADER database listed loxoprofen as a suspect drug, without indicating any concomitant drug interactions. In conclusion, our findings suggest that loxoprofen and etodolac may be associated with viral encephalopathy. Accordingly, prudence is recommended when using loxoprofen in older individuals with viral infections. (Keyword) Adolescent / Adult / Aged / Aged, 80 and over / Child / Female / Humans / Male / Middle Aged / Young Adult / Adverse Drug Reaction Reporting Systems / Anti-Inflammatory Agents, Non-Steroidal / Brain Diseases / Databases, Factual / Japan / Phenylpropionates / United States / United States Food and Drug Administration (Link to Publication Site) ● Publication site (DOI): 10.1691/ph.2024.4506 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38877682 ● Search Scopus @ Elsevier (PMID): 38877682 ● Search Scopus @ Elsevier (DOI): 10.1691/ph.2024.4506 (DOI: 10.1691/ph.2024.4506, PubMed: 38877682)
2.	Kei Kawada, Tomoaki Ishida, Hitoshi Fukuda, Yuki Hyohdoh, Toru Kubo, Tomoyuki Hamada, Yuichi Baba, Toshinobu Hayashi, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda, Hiroaki Kitaoka and Keisuke Ishizawa : Effects of renin-angiotensin system inhibitor and beta-blocker use on mortality in older patients with heart failure with reduced ejection fraction in Japan., Frontiers in Cardiovascular Medicine, Vol.11, 2024. (Summary) RAS inhibitors prevented all-cause mortality and cardiac death at all ages, whereas beta-blockers had different effects depending on the patient's age. This study suggested that the choice of beta-blockers and RAS inhibitors is more important in older patients with HFrEF than in younger patients with the same condition. (Link to Publication Site) ● Publication site (DOI): 10.3389/fcvm.2024.1377228 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38883984 ● Search Scopus @ Elsevier (PMID): 38883984 ● Search Scopus @ Elsevier (DOI): 10.3389/fcvm.2024.1377228 (DOI: 10.3389/fcvm.2024.1377228, PubMed: 38883984)
3.	Kei Kawada, Tomoaki Ishida, Shumpei Morisawa, Kohei Jobu, Youichirou Higashi, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda, Mitsuhiko Miyamura and Keisuke Ishizawa : Atractylodes lancea (Thunb.) DC. [Asteraceae] rhizome-derived exosome-like nanoparticles suppress lipopolysaccharide-induced inflammation in murine microglial cells., Frontiers in Pharmacology, Vol.15, 2024. (Summary) Exosome-like nanoparticles (ELNs) mediate interspecies intercellular communications and modulate gene expression. In this study, we isolated and purified ELNs from the dried rhizome of Atractylodes lancea (Thunb.) DC. [Asteraceae] (ALR-ELNs), a traditional natural medicine, and investigated their potential as neuroinflammatory therapeutic agents. ALR-ELN samples were isolated and purified using differential centrifugation, and their physical features and microRNA contents were analyzed through transmission electron microscopy and RNA sequencing, respectively. BV-2 microglial murine cells and primary mouse microglial cells were cultured , and their ability to uptake ALR-ELNs was explored using fluorescence microscopy. The capacity of ALR-ELNs to modulate the anti-inflammatory responses of these cells to lipopolysaccharide (LPS) exposure was assessed through mRNA and protein expression analyses. Overall, BV-2 cells were found to internalize ALR-ELNs, which comprised three microRNAs (ath-miR166f, ath-miR162a-5p, and ath-miR162b-5p) that could have anti-inflammatory activity. Pretreatment of BV-2 cells with ALR-ELN prevented the pro-inflammatory effects of LPS stimulation by significantly reducing the levels of nitric oxide, interleukin-1β, interleukin-6, and tumor necrosis factor-α. Notably, the mRNA levels of , and in BV-2 cells, which increased upon LPS exposure, were significantly reduced following ALR-ELN treatment. Moreover, the mRNA levels of heme oxygenase 1, , and also increased significantly following ALR-ELN treatment. In addition, pretreatment of primary mouse microglial cells with ALR-ELN prevented the pro-inflammatory effects of LPS stimulation by significantly reducing the levels of nitric oxide. Our findings indicate that ALR-ELNs exhibit anti-inflammatory effects on murine microglial cells. Further validation may prove ALR-ELNs as a promising neuroinflammatory therapeutic agent. (Link to Publication Site) ● Publication site (DOI): 10.3389/fphar.2024.1302055 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38738173 ● Search Scopus @ Elsevier (PMID): 38738173 ● Search Scopus @ Elsevier (DOI): 10.3389/fphar.2024.1302055 (DOI: 10.3389/fphar.2024.1302055, PubMed: 38738173)
4.	Toshinobu Hayashi, Mototsugu Shimokawa, Koichi Matsuo, Kei Kawada, Takafumi Nakano and Takashi Egawa : Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy., Expert Opinion on Pharmacotherapy, Vol.24, No.18, 2221-2226, 2024. (Summary) A 5-day regimen triplet antiemetic prophylaxis with APR decreased long-delayed vomiting compared with a 3-day regimen in patients receiving CDDP-based chemotherapy. However, the 5-day regimen showed no advantage over the 3-day regimen against long-delayed nausea. (Keyword) Humans / Antiemetics / Antineoplastic Agents / Aprepitant / Cisplatin / Nausea / Vomiting (Link to Publication Site) ● Publication site (DOI): 10.1080/14656566.2023.2288288 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38009903 ● Summary page in Scopus @ Elsevier: 2-s2.0-85178202898 (DOI: 10.1080/14656566.2023.2288288, PubMed: 38009903, Elsevier: Scopus)
5.	Fuka Aizawa, Haruna Kajimoto, Okabayashi Ami, Daishi Moriyama, Kenta Yagi, Takahashi Shimon, sonoda Yuhei, shibata Takahiro, Mitsuhiro Goda, Takahiro Niimura, Yuki Izawa-Ishizawa, Hirofumi Hamano, Kei Kawada, Yoshito Zamami and Keisuke Ishizawa : Statins ameliorate oxaliplatin- and paclitaxel-induced peripheral neuropathy via glutathione-S-transferase, Neurochemistry International, Vol.180, 105863, 2024.
6.	Okamoto Naoki, Kenta Yagi, Imawaka Sayaka, Takaoka Mayu, Fuka Aizawa, Takahiro Niimura, Mitsuhiro Goda, Miyata Koji, Kei Kawada, Yuki Izawa-Ishizawa, Satoshi Sakaguchi and Keisuke Ishizawa : A Novel Allosteric Inhibitor of BCR-ABL1, Shows Synergistic Effects When Used in Combination with Imatinib with or without Drug Resistance., Pharmacology Research & Perspectives, Vol.12, No.4, e1214, 2024.
7.	Tomoaki Ishida, Kei Kawada, Kohei Jobu, Shumpei Morisawa, Tetsushi Kawazoe, Satomi Nishimura, Keita Akagaki, Saburo Yoshioka and Mitsuhiko Miyamura : Exosome-like nanoparticles derived from Allium tuberosum prevent neuroinflammation in microglia-like cells., The Journal of Pharmacy and Pharmacology, Vol.75, No.10, 1322-1331, 2023. (Summary) A-ELNs can alleviate microglial inflammation. Their effects can be potentiated by incorporating anti-inflammatory drugs, such as dexamethasone, making them potential therapeutic agents or drug-delivery carriers for neuroinflammation. (Keyword) Mice / Animals / Microglia / Chive / Neuroinflammatory Diseases / Exosomes / Lipopolysaccharides / Inflammation / Anti-Inflammatory Agents / Cytokines / Nanoparticles / Dexamethasone / Nitric Oxide Synthase Type II / Nitric Oxide / NF-kappa B / Mammals (Link to Publication Site) ● Publication site (DOI): 10.1093/jpp/rgad062 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37390476 ● Search Scopus @ Elsevier (PMID): 37390476 ● Search Scopus @ Elsevier (DOI): 10.1093/jpp/rgad062 (DOI: 10.1093/jpp/rgad062, PubMed: 37390476)
8.	Hitoshi Fukuda, Yuki Hyohdoh, Hitoshi Ninomiya, Yusuke Ueba, Tsuyoshi Ohta, Yu Kawanishi, Tomohito Kadota, Fumihiro Hamada, Naoki Fukui, Motonobu Nonaka, Kei Kawada, Maki Fukuda, Yo Nishimoto, Nobuhisa Matsushita, Yuji Nojima, Namito Kida, Satoru Hayashi, Tomohiko Izumidani, Hiroyuki Nishimura, Akihito Moriki and Tetsuya Ueba : Impact of areal socioeconomic status on prehospital delay of acute ischaemic stroke: retrospective cohort study from a prefecture-wide survey in Japan., BMJ Open, Vol.13, No.8, e075612, 2023. (Summary) This article is linked to a clinical trial to UMIN000050189, No.: R000057166 and relates to its Result stage. (Keyword) Humans / Stroke / Retrospective Studies / Japan / Brain Ischemia / Tissue Plasminogen Activator / Ischemic Stroke / Social Class / Emergency Medical Services (Link to Publication Site) ● Publication site (DOI): 10.1136/bmjopen-2023-075612 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37620264 ● Summary page in Scopus @ Elsevier: 2-s2.0-85168747962 (DOI: 10.1136/bmjopen-2023-075612, PubMed: 37620264, Elsevier: Scopus)
9.	Tomoaki Ishida, Shumpei Morisawa, Kohei Jobu, Kei Kawada, Saburo Yoshioka and Mitsuhiko Miyamura : rhizome derived exosome-like nanoparticles prevent alpha-melanocyte stimulating hormone-induced melanogenesis in B16-F10 melanoma cells., Biochemistry and Biophysics Reports, Vol.35, 101530, 2023. (Summary) Aberrant melanin overproduction can significantly impact an individual's appearance and cause mental and psychological distress. Current inhibitors of melanin production exert harmful side effects due to inadequate selectivity; thus a need to develop more selective melanin synthesis inhibitors is necessary. Extracellular vesicles are important agents of intercellular signalling in prokaryotes and eukaryotes. Recently, plant-derived nanoparticles, similar to mammalian exosomes, have attracted attention for their use in health research. In this study, to investigate the potential of plant-derived exosome-like nanoparticles (ELNs) as inhibitors of melanin production, we used hot water to extract ELNs from the rhizome of (A-ELNs). The size of A-ENLs ranged from 34 to 401 nm and carried three microRNA: ath-miR166f, ath-miR162a-5p, and ath-miR162b-5p. These A-ENLs were applied to B16-F10 melanoma cells treated with α-melanocyte-stimulating hormone (α-MSH). After A-ELNs were taken up by B16-F10 cells, their melanin levels were significantly reduced. Furthermore, A-ELNs significantly reduced tyrosinase activity in B16-F10 cells and mRNA expression of microphthalmia-associated transcription factor (), tyrosinase, tyrosinase-related protein 1, and DOPA chrome tautomerase. These results suggest that A-ELN suppresses melanogenic enzymes expression by downregulating , thereby inhibiting melanin synthesis. Hence, A-ELN can be developed into a novel topical drug after additional studies and optimization. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bbrep.2023.101530 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37637942 ● Search Scopus @ Elsevier (PMID): 37637942 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bbrep.2023.101530 (DOI: 10.1016/j.bbrep.2023.101530, PubMed: 37637942)
10.	Toshinobu Hayashi, Mototsugu Shimokawa, Koichi Matsuo, Masanobu Uchiyama, Kei Kawada, Takafumi Nakano and Takashi Egawa : Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy., Oncology, Vol.101, No.9, 584-590, 2023. (Summary) Careful patient selection and symptom monitoring are needed when implementing the DEX-sparing strategy in triplet antiemetic prophylaxis for patients undergoing CBDCA-based chemotherapy. Furthermore, additional strategies may be needed to achieve better control of delayed CINV. (Keyword) Humans / Aprepitant / Palonosetron / Antiemetics / Carboplatin / Dexamethasone / Isoquinolines / Quinuclidines / Nausea / Vomiting / Antineoplastic Combined Chemotherapy Protocols / Antineoplastic Agents (Link to Publication Site) ● Publication site (DOI): 10.1159/000531318 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37276851 ● Search Scopus @ Elsevier (PMID): 37276851 ● Search Scopus @ Elsevier (DOI): 10.1159/000531318 (DOI: 10.1159/000531318, PubMed: 37276851)
11.	T Kawazoe, T Ishida, K Jobu, Kei Kawada, S Yoshioka and M Miyamura : Analysis of Urinary Retention Caused by Selective β 3-adrenoceptor Agonists Using the Japanese Adverse Drug Event Report Database (JADER)., Die Pharmazie, Vol.78, No.5, 56-62, 2023. (Summary) Overactive bladder (OAB) is a frequent chronic disorder which impairs quality of life by frequent, uncontrollable urination. Newly developed selectiveβ 3-adrenoceptor agonists (sβ 3-agonists) have the same efficacy in treating OAB but significantly fewer side effects than the traditionally used anti-muscarinics. However, safety data on these compounds are scarce. In this study, we analysed the occurrence of adverse effects in patients taking sβ 3-agonists and their characteristics using the JADER database. The most frequently reported adverse effect associated with the use of sβ 3-agonists was urinary retention [mirabegron; crude reporting odds ratios (ROR): 62.1, 95% confidence interval (CI): 52.0-73.6, P<0.001, vibegron; crude ROR: 250, 95% CI : 134-483, P<0.001]. Data from patients with urinary retention were stratified by sex. In both men and women, the rate of urinary retention was higher when using the mirabegron/anti-muscarinic drug when compared to mirabegron monotherapy; its occurrence was higher in men with a history of benign prostatic hypertrophy than in those without. Weibull analysis showed that approximately 50% of sβ 3 agonist-induced urinary retention occurred within 15 days after initiation of treatment, and then gradually decreased. Although sβ 3-agonists are useful against OAB, they may induce several side effects, especially urinary retention, which can further evolve into more severe conditions. Urinary retention occurs more frequently in patients concomitantly taking medication that either increases urethral resistance or has organic factors that block the urethra. When using sβ 3-agonists, the concomitantly used medications and underlying diseases should be thoroughly reviewed, and safety monitoring should be instituted early during the treatment. (Keyword) Male / Humans / Female / Urinary Retention / Muscarinic Antagonists / Quality of Life / East Asian People / Adrenergic beta-3 Receptor Agonists / Urinary Bladder, Overactive / Drug-Related Side Effects and Adverse Reactions / Receptors, Adrenergic / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1691/ph.2023.3509 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37189265 ● Search Scopus @ Elsevier (PMID): 37189265 ● Search Scopus @ Elsevier (DOI): 10.1691/ph.2023.3509 (DOI: 10.1691/ph.2023.3509, PubMed: 37189265)
12.	Kei Kawada, Tomoaki Ishida, Kohei Jobu, Shumpei Morisawa, Motoki Nishida, Naohisa Tamura, Saburo Yoshioka and Mitsuhiko Miyamura : Glycyrrhizae Radix suppresses lipopolysaccharide- and diazepam-induced nerve inflammation in the hippocampus, and contracts the duration of pentobarbital- induced loss of righting reflex in a mouse model., Journal of Natural Medicines, Vol.77, No.3, 561-571, 2023. (Summary) Nerve inflammation is linked to the development of various neurological disorders. This study aimed to examine whether Glycyrrhizae Radix effectively influences the duration of the pentobarbital-induced loss of righting reflex, which may increase in a mouse model of lipopolysaccharide (LPS)-induced nerve inflammation and diazepam-induced γ-aminobutyric acid receptor hypersensitivity. Furthermore, we examined the anti-inflammatory effects of Glycyrrhizae Radix extract on LPS-stimulated BV2 microglial cells, in vitro. Treatment with Glycyrrhizae Radix significantly decreased the duration of pentobarbital-induced loss of righting reflex in the mouse model. Furthermore, treatment with Glycyrrhizae Radix significantly attenuated the LPS-induced increases in interleukin-1β, interleukin-6, and tumor necrosis factor-alpha at the mRNA level, and it significantly reduced the number of ionized calcium-binding adapter molecule-1-positive cells in the hippocampal dentate gyrus 24 h after LPS treatment. Treatment with Glycyrrhizae Radix also suppressed the release of nitric oxide, interleukin-1β, interleukin-6, and tumor necrosis factor protein in culture supernatants of LPS-stimulated BV2 cells. In addition, glycyrrhizic acid and liquiritin, active ingredients of Glycyrrhizae Radix extract, reduced the duration of pentobarbital-induced loss of righting reflex. These findings suggest that Glycyrrhizae Radix, as well as its active ingredients, glycyrrhizic acid and liquiritin, may be effective therapeutic agents for the treatment of nerve inflammation-induced neurological disorders. (Keyword) Mice / Animals / Interleukin-6 / Lipopolysaccharides / Glycyrrhizic Acid / Pentobarbital / Interleukin-1beta / Diazepam / Reflex, Righting / Inflammation / Hippocampus / Plant Extracts / Glycyrrhiza / Drugs, Chinese Herbal (Link to Publication Site) ● Publication site (DOI): 10.1007/s11418-023-01700-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37115471 ● Search Scopus @ Elsevier (PMID): 37115471 ● Search Scopus @ Elsevier (DOI): 10.1007/s11418-023-01700-2 (DOI: 10.1007/s11418-023-01700-2, PubMed: 37115471)
13.	Naohisa Tamura, Tomoaki Ishida, Kei Kawada, Kohei Jobu, Shumpei Morisawa, Saburo Yoshioka and Mitsuhiko Miyamura : Risk Factors for Anticancer Drug-Induced Hyponatremia: An Analysis Using the Japanese Adverse Drug Report (JADER) Database., Medicina, Vol.59, No.1, 2023. (Summary) Hyponatremia has been reported in women and patients with lung cancer receiving cisplatin, with a growing trend in the number of elderly patients receiving cisplatin. Furthermore, since the onset of hyponatremia during cisplatin administration is frequently reported within 10 days, patient information should be thoroughly examined before and monitored throughout the administration, which can contribute to the early detection and prevention of hyponatremia. (Keyword) Aged / female / Humans / Antineoplastic Agents / Cisplatin / Electrolytes / Hyponatremia / Kidney Neoplasms / Lung Neoplasms / Risk Factors (Link to Publication Site) ● Publication site (DOI): 10.3390/medicina59010166 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36676789 ● Search Scopus @ Elsevier (PMID): 36676789 ● Search Scopus @ Elsevier (DOI): 10.3390/medicina59010166 (DOI: 10.3390/medicina59010166, PubMed: 36676789)
14.	門田亜紀, 加賀屋陽子, 岡本茉奈実, 上杉粋世, 島﨑玲可, 齋藤展子, 山本順子, 宅間大祐, 藤田博子, Kei Kawada, 常風興平 and 宮村充彦 : 薬薬連携を通じたアドレナリン自己注射手技獲得に対する評価, 日本小児臨床薬理学会雑誌 / 日本小児臨床薬理学会 [編], Vol.36, No.1, 100-106, 2023. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520860631056559744 (CiNii: 1520860631056559744)
15.	Keita Akagaki, Aki Kadota, Tomoaki Ishida, Takaya Sagawa, Yoko Kagaya, Kei Kawada, Naohisa Tamura, Hisashi Shiraishi, Kohei Jobu, Saburo Yoshioka, Masaki Yamamoto, Mikiya Fujieda and Mitsuhiko Miyamura : [Development and Assessment of a New Oral Selenium Fast-disintegrating Tablets]., Journal of the Pharmaceutical Society of Japan, Vol.143, No.12, 1039-1046, 2023. (Summary) are expected to improve the adherence and quality of life of patients who require selenium supplementation. (Keyword) Humans / Selenium / Quality of Life / Mannitol / Tablets / Drug Packaging / Administration, Oral / Solubility / Drug Compounding (Link to Publication Site) ● Publication site (DOI): 10.1248/yakushi.23-00101 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38044109 ● Search Scopus @ Elsevier (PMID): 38044109 ● Search Scopus @ Elsevier (DOI): 10.1248/yakushi.23-00101 (DOI: 10.1248/yakushi.23-00101, PubMed: 38044109)
16.	Kei Kawada, Tomoaki Ishida, Kohei Jobu, Shumpei Morisawa, Naohisa Tamura, Shouhei Sugimoto, Masafumi Okazaki, Saburo Yoshioka and Mitsuhiko Miyamura : Adverse Reaction Profiles Related to Gastrointestinal Bleeding Events Associated with BCR-ABL Tyrosine Kinase Inhibitors., Medicina, Vol.58, No.10, 2022. (Summary) : Specific TKIs and patient characteristics were associated with gastrointestinal bleeding. Our results aid the prompt identification and treatment of TKI-related gastrointestinal bleeding. (Keyword) Male / Female / Humans / Dasatinib / Imatinib Mesylate / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Pyrimidines / Protein Kinase Inhibitors / Gastrointestinal Hemorrhage (Link to Publication Site) ● Publication site (DOI): 10.3390/medicina58101495 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36295654 ● Search Scopus @ Elsevier (PMID): 36295654 ● Search Scopus @ Elsevier (DOI): 10.3390/medicina58101495 (DOI: 10.3390/medicina58101495, PubMed: 36295654)
17.	Kei Kawada, Toru Kubo, Tomoaki Ishida, Kohei Jobu, Shumpei Morisawa, Tomoyuki Hamada, Yuiti Baba, Kazuya Kawai, Yoko Nakaoka, Toshikazu Yabe, Takashi Furuno, Eisuke Yamada, Hitoshi Fukuda, Tsuyoshi Ohta, Toshinobu Hayashi, Hiroaki Kitaoka and Mitsuhiko Miyamura : Assisted Living and Medication Adherence in Super-aged Patients With Heart Failure in the Japanese Population., Journal of Cardiovascular Pharmacology, Vol.79, No.4, 467-471, 2022. (Summary) Poor adherence to medication in patients with heart failure (HF) is associated with poor clinical outcomes. Although social support has been reported to improve medication adherence in patients with HF, the detailed underlying mechanism of this association is unclear. This study investigated appropriate social support types to ensure medication adherence, as well as patient characteristics that benefit from such social support in patients with HF. This was a retrospective observational study investigating the association of social support with medication adherence in 824 patients with HF who were registered in a prospective multicenter database. First, we analyzed the association between social support types and poor medication adherence leading to hospitalization. An interaction analysis was performed to detect patients' characteristics that benefited most from social support in terms of medical adherence. Fifty patients (6.1%) were hospitalized for poor adherence to medications. Multivariable analysis revealed that not receiving assisted living, which was defined as having supporting individuals at least once a week, was independently associated with poor medication adherence-related hospitalization. An interaction analysis revealed that patients with dementia benefited from assisted living significantly, whereas male patients or current smokers did not. Summarily, assisted living at least once a week was appropriate for improving medication adherence in patients with HF and was particularly effective in patients with dementia. Performed in a super-aging region in Japan, this study may also suggest the relevance of social support in preventing HF exacerbation in other developed countries that will experience an aging society in the near future. (Keyword) Aged / Dementia / Heart Failure / Humans / Japan / Male / Medication Adherence / Prospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1097/FJC.0000000000001212 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34983904 ● Search Scopus @ Elsevier (PMID): 34983904 ● Search Scopus @ Elsevier (DOI): 10.1097/FJC.0000000000001212 (DOI: 10.1097/FJC.0000000000001212, PubMed: 34983904)
18.	Kei Kawada, Tomoaki Ishida, Kohei Jobu, Shumpei Morisawa, Tetsushi Kawazoe, Motoki Nishida, Satomi Nishimura, Naohisa Tamura, Saburo Yoshioka and Mitsuhiko Miyamura : Yokukansan suppresses neuroinflammation in the hippocampus of mice and decreases the duration of lipopolysaccharide- and diazepam-mediated loss of righting reflex induced by pentobarbital., Journal of Natural Medicines, Vol.76, No.3, 634-644, 2022. (Summary) Neuroinflammation is associated with the development of hypoactive delirium, which results in poor clinical outcomes. Drugs effective against hypoactive sur have not yet been established. Yokukansan has an anti-neuroinflammatory effect, making it potentially effective against hypoactive delirium. This study aimed to examine the effect of Yokukansan on the pentobarbital-induced loss of righting reflex duration extended with lipopolysaccharide (LPS)-induced neuroinflammation and diazepam-induced gamma-aminobutyric acid receptor stimulation in a mouse model. The active ingredients in Yokukansan and its anti-neuroinflammatory effect on the hippocampus were also investigated. Furthermore, we examined the in vitro anti-inflammatory effects of Yokukansan on LPS-stimulated BV2 cells, a murine microglial cell line. Findings revealed that treatment with Yokukansan significantly decreased the duration of pentobarbital-induced loss of righting reflex by attenuating the LPS-induced increase in interleukin-6 and tumor necrosis factor-alpha levels in the hippocampus. Moreover, treatment with Yokukansan significantly decreased the number of ionized calcium-binding adapter molecule-1-positive cells in the hippocampal dentate gyrus after 24 h of LPS administration. In addition, glycyrrhizic acid, an active ingredient in Yokukansan, partially decreased the duration of pentobarbital-induced loss of righting reflex. Treatment with Yokukansan also suppressed the expression of inducible nitric oxide, interleukin-6, and tumor necrosis factor mRNA in LPS-stimulated BV2 cells. Thus, these findings suggest that Yokukansan and glycyrrhizic acid may be effective therapeutic agents for treating neuroinflammation-induced hypoactive delirium. (Keyword) Animals / Delirium / Diazepam / Drugs, Chinese Herbal / Glycyrrhizic Acid / Hippocampus / Inflammation / Interleukin-6 / Lipopolysaccharides / Mice / NF-kappa B / Neuroinflammatory Diseases / Pentobarbital / Reflex, Righting / Tumor Necrosis Factor-alpha (Link to Publication Site) ● Publication site (DOI): 10.1007/s11418-022-01612-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35257304 ● Search Scopus @ Elsevier (PMID): 35257304 ● Search Scopus @ Elsevier (DOI): 10.1007/s11418-022-01612-7 (DOI: 10.1007/s11418-022-01612-7, PubMed: 35257304)
19.	Yanglan Ou, Kohei Jobu, Tomoaki Ishida, Shumpei Morisawa, Hiroko Fujita, Kei Kawada, Saburo Yoshioka and Mitsuhiko Miyamura : Saikokeishikankyoto extract alleviates muscle atrophy in KKAy mice., Journal of Natural Medicines, Vol.76, No.2, 379-388, 2022. (Summary) Sarcopenic obesity is associated with increased visceral fat and decreased muscle mass, resulting in decreased insulin sensitivity, increased production of inflammatory cytokines, and oxidative stress. In this study, we first evaluated the effects of herbal medicines on the transcriptional activity of the Sirtuin 1 (sirt1) promoter in vitro as an indicator of their therapeutic effect. Our data suggested that hot water Saikokeishikankyoto (SKK) extracts increased sirt1 transcriptional activity in vitro, identifying it as a candidate therapeutic for evaluation in the KKAy type 2 diabetic obesity mouse model. These in vivo evaluations revealed that SKK treatment increased the wet weight and muscle fiber content in cross sections of the gastrocnemius muscle (GA) and restored motor function in these animals. In addition, SKK treatment reduced tumor necrosis factor-α (TNFα) expression in the sera and suppressed Atrogin1 and MuRF1 transcription in the GA samples. This treatment also increased sirt1 expression in these tissues. These results suggest that SKK inhibits skeletal muscle atrophy and improves motor function in KKAy mice by suppressing inflammation. In actual clinical practice, SKK is expected to inhibit muscle atrophy and improve motor dysfunction in sarcopenic obesity. (Keyword) Animals / Diabetes Mellitus, Experimental / Mice / Muscle Fibers, Skeletal / Muscle, Skeletal / Muscular Atrophy / Obesity / Plant Extracts / Promoter Regions, Genetic / Sarcopenia / Sirtuin 1 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11418-021-01590-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34997408 ● CiNii @ National Institute of Informatics (CRID): 1360294643793279360 ● Summary page in Scopus @ Elsevier: 2-s2.0-85122528809 (DOI: 10.1007/s11418-021-01590-2, PubMed: 34997408, CiNii: 1360294643793279360, Elsevier: Scopus)
20.	Tomoaki Ishida, Kohei Jobu, Kei Kawada, Shumpei Morisawa, Tetsushi Kawazoe, Hisashi Shiraishi, Hiroko Fujita, Satomi Nishimura, Hitomi Kanno, Mitsue Nishiyama, Kazuo Ogawa, Yasuyo Morita, Kazuhiro Hanazaki and Mitsuhiko Miyamura : Impact of Gut Microbiota on the Pharmacokinetics of Glycyrrhizic Acid in Yokukansan, a Kampo Medicine., Biological & Pharmaceutical Bulletin, Vol.45, No.1, 104-113, 2022. (Summary) Individual differences in gut microbiota can affect the pharmacokinetics of drugs. Yokukansan is a traditional Japanese kampo medicine used to treat peripheral symptoms of dementia and delirium. A study examining the pharmacokinetics of the components of yokukansan reported large individual differences in the pharmacokinetics of glycyrrhizic acid (GL). It is known that GL is metabolized by intestinal bacteria to glycyrrhetinic acid (GA), which is absorbed in the gastrointestinal tract. Thus, the gut microbiota may affect GL pharmacokinetics. We aimed to clarify the relationship between the gut microbiota composition and pharmacokinetics of GL in yokukansan. Mice were orally administered yokukansan, following the administration of various antibiotics, and the plasma concentration of GA and composition of gut microbiota were measured. The GA plasma concentration was low in mice treated with amoxicillin and vancomycin. The composition of gut microbiota revealed a different pattern from that of the control group. Mice with low plasma levels of GA had lower levels of the phylum Bacteroides and Firmicutes. Additionally, bacteria, such as those belonging to the genera Parabaceroides, Bacteroides, Ruminococcus and an unknown genus in families Lachnospiraceae and Ruminococcaceae, exerted positive correlations between the gene copies and plasma GA levels. These bacteria may contribute to the absorption of GA in the gastrointestinal tract, and multiple bacteria may be involved in GL pharmacokinetics. The pharmacokinetics of GL may be predicted by evaluating the composition of gut bacteria, rather than by evaluating the amount of a single bacterium. (Keyword) Animals / Drugs, Chinese Herbal / Gastrointestinal Microbiome / Glycyrrhizic Acid / Humans / Medicine, Kampo / Mice (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b21-00658 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34980772 ● CiNii @ National Institute of Informatics (CRID): 1390853567321738496 ● Summary page in Scopus @ Elsevier: 2-s2.0-85123191227 (DOI: 10.1248/bpb.b21-00658, PubMed: 34980772, CiNii: 1390853567321738496, Elsevier: Scopus)
21.	Shohei Sugimoto, Tomoaki Ishida, Kei Kawada, Kohei Jobu, Shumpei Morisawa, Naohisa Tamura, Daisuke Takuma, Saburo Yoshioka and Mitsuhiko Miyamura : Central Nervous System Ischemia Associated with Bevacizumab: An Analysis of the Japanese Adverse Drug Event Report Database., Biological & Pharmaceutical Bulletin, Vol.45, No.12, 1805-1811, 2022. (Summary) Bevacizumab is an inhibitor of vascular endothelial growth factor (VEGF) that prevents tumor growth. While bevacizumab is therapeutically effective, it induces several adverse events. Among these, central nervous system (CNS) ischemia can lead to death or permanent disability. In this study, we reviewed the Japanese Adverse Drug Event Report database to analyze the occurrence of CNS ischemia after bevacizumab administration. Significant associations between the occurrence of CNS ischemia and bevacizumab use were detected (adjusted reporting odds ratios (ROR): 2.68, 95% confidence interval (CI): 2.00-3.59, p < 0.001). Furthermore, an association between diagnosis of glioma and bevacizumab use was also detected (p < 0.001). These events occurred early after the start of treatment and then gradually decreased; however, more than half of CNS ischemia events were reported beyond 30 d after the first administration. In addition, a logistic regression suggested that CNS ischemia caused by bevacizumab was associated with glioma, underlying hypertension and aging. A poor prognosis was reported for several cases occurring in elderly patients (over 60 years of age). Although bevacizumab is a useful pharmacological treatment for cancer, caution should be taken to avoid severe adverse events. Accordingly, the patient's general and medical condition should be carefully examined before initiating treatment, and blood pressure should be continuously assessed throughout treatment with bevacizumab to prevent CNS ischemia. (Keyword) Aged / Humans / Middle Aged / Pharmaceutical Preparations / Bevacizumab / Japan / Vascular Endothelial Growth Factor A / Drug-Related Side Effects and Adverse Reactions / central nervous system / ischemia / Glioma (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b22-00496 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36450533 ● CiNii @ National Institute of Informatics (CRID): 1390012801498764160 ● Summary page in Scopus @ Elsevier: 2-s2.0-85143104507 (DOI: 10.1248/bpb.b22-00496, PubMed: 36450533, CiNii: 1390012801498764160, Elsevier: Scopus)
22.	Kei Kawada, Tomoaki Ishida, Kohei Jobu, Tsuyoshi Ohta, Hitoshi Fukuda, Shumpei Morisawa, Tetsushi Kawazoe, Naohisa Tamura and Mitsuhiko Miyamura : Association of Aggression and Antiepileptic Drugs: Analysis Using the Japanese Adverse Drug Event Report (JADER) Database., Biological & Pharmaceutical Bulletin, Vol.45, No.6, 720-723, 2022. (Summary) Aggression is the most common adverse effect of antiepileptic drugs (AEDs). This study aimed to investigate the association of aggression with AED use. The reporting odds ratio (ROR) from adverse event reports, submitted to the Japanese Adverse Drug Event Report database between 2004 and 2020, was used to calculate and investigate the association between AEDs and aggression. We also analyzed the association of aggression with the combined use of AEDs and the relationship between AED-associated aggression and patient characteristics. A total of 433 patients developed aggression. Significant aggression signals were detected for perampanel (crude ROR: 325.04, 95% confidence interval (CI): 118.48-752.58, p < 0.01), levetiracetam (crude ROR: 17.14, 95% CI: 10.33-26.90, p < 0.01), lacosamide (crude ROR: 16.90, 95% CI: 2.02-62.51, p < 0.01), lamotrigine (crude ROR: 15.98, 95% CI: 9.99-24.39, p < 0.01), valproate (crude ROR: 6.68, 95% CI: 4.27-10.02, p < 0.01), and carbamazepine (crude ROR: 2.47, 95% CI: 1.17-4.59, p < 0.01). The combined therapy with perampanel and levetiracetam had a significant aggression signal (adjusted ROR: 25.90, 95% CI: 1.14-59.10, p < 0.01). In addition, we found that aggression frequently occurred in patients <60 year (adjusted ROR: 2.88, 95% CI: 1.49-5.56, p < 0.01) treated with levetiracetam. These results may be useful for minimizing the risk of aggression during the treatment of AEDs. (Keyword) Adverse Drug Reaction Reporting Systems / Aggression / Anticonvulsants / Drug-Related Side Effects and Adverse Reactions / Humans / Japan / Levetiracetam (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b21-00954 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35650100 ● CiNii @ National Institute of Informatics (CRID): 1390855201298938112 ● Summary page in Scopus @ Elsevier: 2-s2.0-85131270763 (DOI: 10.1248/bpb.b21-00954, PubMed: 35650100, CiNii: 1390855201298938112, Elsevier: Scopus)
23.	Tomoaki Ishida, Kohei Jobu, Shumpei Morisawa, Kei Kawada, Saburo Yoshioka and Mitsuhiko Miyamura : Juzentaihoto Suppresses Muscle Atrophy in KKAy Mice., Biological & Pharmaceutical Bulletin, Vol.45, No.7, 888-894, 2022. (Summary) In obese patients with type 2 diabetes, reduced insulin sensitivity, increased production of inflammatory cytokines, and increased oxidative stress were observed, which lead to decreased protein synthesis and increased proteolysis in the skeletal muscles. Juzentaihoto (JTT) is herbal medicine and we have previously reported that the administration of JTT hot water extract alleviates skeletal muscle atrophy in a mouse model with streptozotocin-induced type 1 diabetes. In this study, we evaluated the inhibitory effects of JTT on muscle atrophy in a mouse model with obesity and type 2 diabetes. JTT was administered to KKAy mice with type 2 diabetic obesity and its effects on the skeletal muscles were evaluated. After JTT administration in KKAy mice, the wet weight and muscle fibre cross-sectional area of gastrocnemius increased and the time duration of exercise in the rotarod test improved. In addition, the serum levels of tumour necrosis factor-α and interleukin-6 decreased, adiponectin levels increased, and homeostasis model assessment for insulin resistance improved. Furthermore, JTT administration decreased the mRNA levels of ubiquitin ligase (atrogin-1, muscle RING-finger protein-1), increased the mRNA levels of Sirtuin1 in gastrocnemius. Our results suggest that JTT improves insulin resistance, suppresses inflammation, and reduces oxidative stress in KKAy mice, thereby suppressing skeletal muscle atrophy. JTT administration in clinical practice is expected to improve muscle atrophy in patients with obesity and type 2 diabetes. (Keyword) Animals / Diabetes Mellitus, Type 2 / Drugs, Chinese Herbal / Insulin Resistance / Mice / Muscular Atrophy / Obesity / RNA, Messenger (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b22-00039 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35786596 ● CiNii @ National Institute of Informatics (CRID): 1390011108717888384 ● Summary page in Scopus @ Elsevier: 2-s2.0-85133251823 (DOI: 10.1248/bpb.b22-00039, PubMed: 35786596, CiNii: 1390011108717888384, Elsevier: Scopus)
24.	Shumpei Morisawa, Kohei Jobu, Tomoaki Ishida, Kei Kawada, Hitoshi Fukuda, Yu Kawanishi, Taku Nakayama, Shinkuro Yamamoto, Naohisa Tamura, Mitsuhiro Takemura, Nao Kagimoto, Tsuyoshi Ohta, Noritaka Masahira, Hideo Fukuhara, Shun-Ichiro Ogura, Tetsuya Ueba, Keiji Inoue and Mitsuhiko Miyamura : Association of 5-aminolevulinic acid with intraoperative hypotension in malignant glioma surgery., Photodiagnosis and Photodynamic Therapy, Vol.37, 2021. (Summary) 5-Aminolevulinic acid administration was associated with intraoperative hypotension in malignant glioma surgery, with increasing age and use of renin-angiotensin system inhibitors boosting the blood pressure-lowering effect of 5-aminolevulinic acid. According to in vitro results, the low blood pressure induced by 5-aminolevulinic acid may be mediated by a nitric oxide increase in vascular endothelial cells. (Keyword) Aminolevulinic Acid / Cohort Studies / Endothelial Cells / Glioma / Humans / Hypotension / Photochemotherapy / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1016/j.pdpdt.2021.102657 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34848378 ● Search Scopus @ Elsevier (PMID): 34848378 ● Search Scopus @ Elsevier (DOI): 10.1016/j.pdpdt.2021.102657 (DOI: 10.1016/j.pdpdt.2021.102657, PubMed: 34848378)
25.	Kei Kawada, Hitoshi Fukuda, Toru Kubo, Tsuyoshi Ohta, Tomoaki Ishida, Shumpei Morisawa, Tetushi Kawazoe, Manami Okamoto, Hiroko Fujita, Kohei Jobu, Yasuyo Morita, Tetsuya Ueba, Hiroaki Kitaoka and Mitsuhiko Miyamura : Added value of anxiolytic benzodiazepines in predictive models on severe delirium in patients with acute decompensated heart failure: A retrospective analysis., PLoS ONE, Vol.16, No.4, 2021. (Summary) The use of anxiolytic benzodiazepines was independently correlated with severe delirium, and their use in models based on conventional risk factors had an additive value for predicting delirium in patients with ADHF. (Keyword) Acute Disease / Age Factors / Aged / Aged, 80 and over / Anti-Anxiety Agents / Benzodiazepines / Critical Care / Delirium / female / heart failure / Humans / Incidence / female / Middle Aged / Patient Admission / Respiration, Artificial / Retrospective Studies / Risk Factors / Severity of Illness Index / Sex Factors / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0250372 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33886657 ● Search Scopus @ Elsevier (PMID): 33886657 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0250372 (DOI: 10.1371/journal.pone.0250372, PubMed: 33886657)
26.	Toshinobu Hayashi, Mototsugu Shimokawa, Fumitaka Mizuki, Koichi Matsuo, Kei Kawada, Takafumi Nakano and Takashi Egawa : Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score-matched analysis., Supportive Care in Cancer, Vol.29, No.9, 5029-5035, 2021. (Summary) RA and APR concerning CINV incidence in lung cancer patients receiving CBDCA-based chemotherapy. Antiemetic regimens of one-day DEX result in poor control of delayed nausea; therefore, we recommend the application of the DEX-sparing strategy only after careful patient selection while considering the development of nausea. (Keyword) Antiemetics / Antineoplastic Agents / Carboplatin / Dexamethasone / Humans / Lung Neoplasms / Nausea / Propensity Score / Vomiting (Link to Publication Site) ● Publication site (DOI): 10.1007/s00520-021-06061-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33590260 ● Search Scopus @ Elsevier (PMID): 33590260 ● Search Scopus @ Elsevier (DOI): 10.1007/s00520-021-06061-8 (DOI: 10.1007/s00520-021-06061-8, PubMed: 33590260)
27.	Toshinobu Hayashi, Mototsugu Shimokawa, Koichi Matsuo, Hirotoshi Iihara, Kei Kawada, Takafumi Nakano and Takashi Egawa : Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis., BMC Cancer, Vol.21, No.1, 2021. (Summary) The CBDCA + PEM regimen has a higher risk of causing delayed nausea than the CBDCA + PTX regimen, and aggressive antiemetic prophylaxis should be offered to patients treated with CBDCA + PEM. (Keyword) Age Factors / Aged / Antiemetics / Antineoplastic Combined Chemotherapy Protocols / Carboplatin / female / Humans / Incidence / Lung Neoplasms / female / Middle Aged / Multicenter Studies as Topic / Nausea / Observational Studies as Topic / Paclitaxel / Pemetrexed / Propensity Score / Prospective Studies / Risk Assessment / Risk Factors / Sex Factors / Vomiting (Link to Publication Site) ● Publication site (DOI): 10.1186/s12885-021-07802-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33451299 ● Search Scopus @ Elsevier (PMID): 33451299 ● Search Scopus @ Elsevier (DOI): 10.1186/s12885-021-07802-y (DOI: 10.1186/s12885-021-07802-y, PubMed: 33451299)
28.	Kei Kawada, Tsuyoshi Ohta, Hitoshi Fukuda, Toshinobu Hayashi, Koudai Tanaka, Toshi Imai, Yasuyo Morita and Mitsuhiko Miyamura : Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis., Annals of Hematology, Vol.99, No.10, 2429-2436, 2020. (Summary) Patients receiving vinca alkaloids for hematological malignancies frequently experience constipation that is unresponsive to laxatives. Research on treatment of vinca alkaloid-induced constipation is limited. This study aimed to determine whether the chloride channel activator lubiprostone ameliorates vinca alkaloid-induced constipation in patients with hematological malignancies. In this retrospective cohort study, vinca alkaloid-induced constipation (grade ≥ 3 using the Common Terminology Criteria for Adverse Events) was investigated in patients treated for hematological malignancies between July 2014 and June 2019 who had already been prescribed osmotic laxatives and additionally received either a stimulant laxative or lubiprostone. Univariate and multivariate analyses were performed to identify the risk factors for persistent constipation after introduction of the second laxative. A propensity score model was used to match 67 patients taking a stimulant laxative and 67 treated with lubiprostone, and the occurrence of intractable constipation was compared between groups. Overall, 203 patients were included, among whom 50 (25%) had constipation. On multivariate analysis, body mass index, opioid use, and addition of lubiprostone were independently associated with constipation. Patients treated with lubiprostone were significantly less likely to experience intractable constipation than did those treated with stimulant laxatives (10% vs. 34%, P = 0.002). Moreover, post-constipation diarrhea was significantly less frequent among patients treated with lubiprostone (42% vs. 63%, P = 0.024). Lubiprostone was more effective than stimulant laxatives at treating vinca alkaloid-induced intractable constipation in patients with hematological malignancies, and its use could enable safe vinca alkaloid chemotherapy. (Keyword) Aged / Aged, 80 and over / Antineoplastic Agents, Phytogenic / Antineoplastic Combined Chemotherapy Protocols / Chloride Channel Agonists / Constipation / Cyclophosphamide / Doxorubicin / Drug Evaluation / Drug Therapy, Combination / Famotidine / female / Hematologic Neoplasms / Humans / Laxatives / Lubiprostone / Lymphoma / Magnesium Oxide / female / Middle Aged / Narcotics / Precursor Cell Lymphoblastic Leukemia-Lymphoma / Prednisone / Propensity Score / Proton Pump Inhibitors / Retrospective Studies / Risk Factors / Sennosides / Vinca Alkaloids / Vincristine (Link to Publication Site) ● Publication site (DOI): 10.1007/s00277-020-04222-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32839869 ● Search Scopus @ Elsevier (PMID): 32839869 ● Search Scopus @ Elsevier (DOI): 10.1007/s00277-020-04222-z (DOI: 10.1007/s00277-020-04222-z, PubMed: 32839869)
29.	中山靖規, 太田剛史, Kei Kawada, 池亜里沙, 津野友里, 中島朱也香 and 加嶋憲作 : 急性期脳卒中患者の嚥下造影検査における食物移送時間を指標とした嚥下訓練食からの離脱予測, General Rehabilitation, Vol.48, No.7, 671-676, 2020. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1522262179959174528 (CiNii: 1522262179959174528)
30.	Tomoaki Ishida, Kei Kawada, Shumpei Morisawa, Kohei Jobu, Yasuyo Morita and Mitsuhiko Miyamura : Risk Factors for Pseudoaldosteronism with Yokukansan Use: Analysis Using the Japanese Adverse Drug Report (JADER) Database., Biological & Pharmaceutical Bulletin, Vol.43, No.10, 1570-1576, 2020. (Summary) Yokukansan is a Kampo formula that is commonly used by the elderly because it is expected to improve peripheral symptoms of dementia and delirium. However, side effects from its use are frequently reported in the elderly. In particular, pseudoaldosteronism caused by the licorice contained in yokukansan leads to hypertension, hypokalemia, and muscle weakness, which may result in death. This study aimed to identify the risk factors of pseudoaldosteronism with yokukansan use. Using cases reported in the Japanese Adverse Drug Report (JADER) database, the reporting odds ratio (ROR) was calculated and compared to assess the risk of pseudoaldosteronism for each licorice-containing Kampo formula. We also analyzed the risk factors for pseudoaldosteronism in patients taking yokukansan. Yokukansan (ROR 2.4, 95% confidence interval (CI) 1.9-2.8; p < 0.001) had a higher risk of pseudoaldosteronism than that of other licorice-containing Kampo formulas. Furthermore, the results of a logistic regression analysis in patients taking yokukansan showed that the licorice dose (OR 1.5, 95% CI 1.2-2.0; p < 0.01), older age (<70 years, OR 5.9, 95% CI 1.8-20; p < 0.01), dementia (OR 2.8, 95% CI 1.6-4.9; p < 0.001), low body weight (<50 kg, OR 2.2, 95% CI 1.1-3.5; p = 0.034) were risk factors for pseudoaldosteronism, Although not significant, treatment with loop diuretics (OR 1.8, 95% CI 0.98-3.5; p = 0.059) tended to increase the risk of pseudoaldosteronism. In summary, patients must understand the risk factors when considering taking yokukansan and reduce the licorice dose they consume. (Keyword) Adolescent / adult / Adverse Drug Reaction Reporting Systems / Age Factors / Aged / data analysis / Databases, Factual / Drugs, Chinese Herbal / female / Humans / Japan / Liddle Syndrome / female / Middle Aged / Risk Factors / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b20-00424 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32999167 ● Search Scopus @ Elsevier (PMID): 32999167 ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b20-00424 (DOI: 10.1248/bpb.b20-00424, PubMed: 32999167)
31.	石本倫子, Kei Kawada, 太田剛史, 筒井敬子 and 岡田由香里 : 輸血副反応報告に関する新運用導入の有用性, 日本輸血細胞治療学会誌, Vol.66, No.6, 750-755, 2020.
32.	Kei Kawada, 太田剛史, 田中聡 and 宮村充彦 : ベンゾジアゼピン系・非ベンゾジアゼピン系睡眠導入薬を慢性的に服用している急性期脳卒中発症患者における安全な睡眠薬選択の検討, Japanese Journal of Pharmaceutical Health Care and Sciences, Vol.45, No.4, 175-181, 2019.
33.	Kei Kawada, Tsuyoshi Ohta, Koudai Tanaka, Mitsuhiko Miyamura and Satoshi Tanaka : Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients., Journal of Stroke & Cerebrovascular Diseases, Vol.28, No.1, 142-148, 2018. (Summary) Addition of suvorexant to ramelteon therapy, rather than a GABA receptor agonist, can improve subjective sleep quality without inducing delirium in acute stroke patients. (Keyword) Aged / Aged, 80 and over / Azepines / Delirium / Drug Therapy, Combination / female / GABA Agonists / Humans / Indenes / Male / Orexin Receptor Antagonists / Receptors, Melatonin / Retrospective Studies / Risk Factors / sleep / Sleep Aids, Pharmaceutical / Sleep Initiation and Maintenance Disorders / Stroke / Treatment Outcome / Triazoles (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jstrokecerebrovasdis.2018.09.024 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30322756 ● Search Scopus @ Elsevier (PMID): 30322756 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jstrokecerebrovasdis.2018.09.024 (DOI: 10.1016/j.jstrokecerebrovasdis.2018.09.024, PubMed: 30322756)
34.	中井梨郁, Kei Kawada, 太田剛史, 山崎真妃呂 and 宮本典文 : 脳神経外科病棟における薬剤師の関わり, 全国自治体病院協議会雑誌, Vol.57, No.6, 942-945, 2018.
35.	岡崎弘志, 田中広大, Kei Kawada, 沼本邦彦 and 時岡孝光 : 当院での整形外科手術における脳梗塞発症と抗血栓薬の服用・休薬の関連性についての検討, 中国・四国整形外科学会雑誌, Vol.30, No.1, 143, 2018.
36.	Kei Kawada, Tsuyoshi Ohta, Koudai Tanaka and Norifumi Miyamoto : Reduction of Nicardipine-Related Phlebitis in Patients with Acute Stroke by Diluting Its Concentration., Journal of Stroke & Cerebrovascular Diseases, Vol.27, No.7, 1783-1788, 2018. (Summary) The simple and appropriate proposition about nicardipine administration lowered maximum nicardipine concentration and reduced the incidence of nicardipine-related phlebitis in patients with acute stroke. (Keyword) Administration, Intravenous / Aged / Aged, 80 and over / Antihypertensive Agents / female / Humans / hypertension / Incidence / Logistic Models / female / Middle Aged / Multivariate Analysis / Nicardipine / Phlebitis / Retrospective Studies / Risk Factors / Severity of Illness Index / Stroke / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jstrokecerebrovasdis.2018.02.013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29519742 ● Search Scopus @ Elsevier (PMID): 29519742 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jstrokecerebrovasdis.2018.02.013 (DOI: 10.1016/j.jstrokecerebrovasdis.2018.02.013, PubMed: 29519742)
37.	中山靖規, 池亜里沙, Kei Kawada and 太田剛史 : 急性期脳卒中患者における食物移送時間と嚥下障害の予後予測, 言語聴覚研究, Vol.14, No.3, 295-296, 2017.
38.	Kei Kawada, Tsuyoshi Ohta, Koudai Tanaka, Naoto Kadoguchi, Souichi Yamamoto and Masanori Morimoto : Risk Factors of Nicardipine-Related Phlebitis in Acute Stroke Patients., Journal of Stroke & Cerebrovascular Diseases, Vol.25, No.10, 2513-2518, 2016. (Summary) The incidence and risk factors of phlebitis were investigated in 358 acute stroke patients from July 2014 to June 2015. (Keyword) Administration, Intravenous / Aged / Aged, 80 and over / Antihypertensive Agents / Dose-Response Relationship, Drug / female / Humans / hypertension / Incidence / Japan / Logistic Models / female / Middle Aged / Multivariate Analysis / Nicardipine / Odds Ratio / Phlebitis / Retrospective Studies / Risk Factors / Stroke / Time Factors / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jstrokecerebrovasdis.2016.06.028 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27423368 ● Search Scopus @ Elsevier (PMID): 27423368 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jstrokecerebrovasdis.2016.06.028 (DOI: 10.1016/j.jstrokecerebrovasdis.2016.06.028, PubMed: 27423368)
39.	田中広大, 山脇まり絵, Kei Kawada, 山本創一 and 服部暁昌 : ビンクリスチンとイトラコナゾール内用液の相互作用を回避するための投与方法の検討, 日本病院薬剤師会雑誌, Vol.50, No.8, 1029-1033, 2014.
40.	松本尚子, Kei Kawada, 澤田努, 北村和之 and 早瀬仁美 : 無医地区巡回診療への電子カルテシステムの導入新システムを通じた薬剤師の役割, 全国自治体病院協議会雑誌, Vol.53, No.4, 568-573, 2014.
41.	田中聡, 服部暁昌, Naoto Kadoguchi, Kei Kawada and 小笠原恵子 : 救急医療におけるハイリスク薬と医療安全管理救急医療における専任薬剤師による医薬品安全管理, 日本臨床救急医学会雑誌, Vol.16, No.3, 301, 2013.
42.	岡崎由紀, Kei Kawada, 服部暁昌, 谷木利勝 and 武田明雄 : 医薬品SPDの導入による薬剤業務の合理化とSPD職員の意識調査, 日本医療マネジメント学会雑誌, Vol.13, 277, 2012.
43.	門口直仁, 田中聡, Kei Kawada, 高平豊 and 服部暁昌 : 救命救急・集中治療領域におけるバンコマイシン血中濃度予測性の検討, Journal of Japanese Society for Emergency Medicine, Vol.15, No.2, 212, 2012.
44.	門口直仁, 田中聡, Kei Kawada, 高平豊 and 服部暁昌 : 救命救急・集中治療領域におけるバンコマイシン血中濃度予測性の検討, Journal of Japanese Society for Emergency Medicine, Vol.15, No.2, 212, 2012.
45.	Kei Kawada, 長崎大武, 田中聡, 服部暁昌 and 田中照夫 : 救命救急センターにおける医薬品安全管理への薬剤師の貢献, Journal of Japnese Society of Hospital Pharmacists, Vol.48, No.2, 181-184, 2012.
46.	Kei Kawada, 田中聡, 公文登代, 山本創一 and 隅田裕夫 : 災害医療支援チームにおける薬剤師の役割, 日本集団災害医学会誌, Vol.16, No.3, 456, 2011.
47.	岡崎由紀, 田中聡, Kei Kawada, 長崎大武 and 服部暁昌 : 手術室における医薬品管理体制の評価, The Journal of Japan Society for Health Care Management, Vol.12, 193, 2011.
48.	田中聡, 村田厚夫, 長崎大武, Kei Kawada and 服部暁昌 : 救急医療における認定薬剤師の誕生と未来高知医療センターにおける薬剤師による救急医療支援業務, Journal of Japanese Society for Emergency Medicine, Vol.14, No.2, 220, 2011.
49.	Kei Kawada, 長崎大武, 田中聡, 服部暁昌 and 寺岡美千代 : 命救急センターにおける医薬品関連インシデントの発生状況, The Journal of Japan Society for Health Care Management, Vol.11, 213, 2010.
50.	田中聡, Kei Kawada, 長崎大武, 服部暁昌 and 田中照夫 : 災害初動時における初期薬剤供給体制についての検討, 日本臨床救急医学会雑誌, Vol.13, No.2, 192, 2010.
51.	Kei Kawada, 田中聡, 服部暁昌, 田中照夫 and 石本倫子 : 当院における尿中乱用薬物検出キット「トライエージDOA」検査の現状, 中毒研究, Vol.21, No.4, 436-437, 2008.
52.	Kei Kawada, 田中聡, 小笠原恵子, 寺岡美代子 and 石原潤子 : 救命救急センターにおける医薬品安全管理への薬剤師の取り組み, Journal of Japanese Society for Emergency Medicine, Vol.11, No.2, 255, 2008.
53.	Yusuke Fujiwara, Kei Kawada, Daiki Takano, Susumu Tanimura, Kei-ichi Ozaki and Michiaki Kohno : Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner., Biochemical and Biophysical Research Communications, Vol.340, No.2, 560-566, 2005. (Summary) Constitutive activation of the PI3 kinase/Akt pathway is associated with the neoplastic phenotype of a large number of human tumor cells. As the anti-apoptotic role of the PI3 kinase/Akt pathway has been established, we have examined whether specific blockade of this pathway sensitizes tumor cells to DNA-damaging agent-induced cytotoxicity by enhancing apoptotic cell death. Although a PI3 kinase inhibitor, LY294002, by itself does not induce apoptotic cell death, LY294002 selectively and markedly enhances the apoptosis-inducing efficacy of doxorubicin: such an enhanced cell death is only detected in tumor cells in which the PI3 kinase/Akt pathway is constitutively activated, and it is totally dependent on the functional p53 pathway. These results suggest that the combination of a PI3 kinase/Akt pathway inhibitor and doxorubicin provides an efficient chemotherapeutic strategy for the treatment of tumor cells in which the PI3 kinase/Akt pathway is constitutively activated and the p53 pathway is functional. (Keyword) Antibiotics, Antineoplastic / Apoptosis / Cell Line, Tumor / Chromones / Doxorubicin / Humans / Morpholines / Phosphatidylinositol 3-Kinases / Phosphoinositide-3 Kinase Inhibitors / Protein Kinase Inhibitors / Proto-Oncogene Proteins c-akt / Signal transduction of proinflammatory cytokine receptors / Tumor Suppressor Protein p53 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bbrc.2005.12.039 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16378598 ● Search Scopus @ Elsevier (PMID): 16378598 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bbrc.2005.12.039 (DOI: 10.1016/j.bbrc.2005.12.039, PubMed: 16378598)

Proceeding of International Conference:

1.	Kenta Yagi, Fuka Aizawa, Takahiro Niimura, Mitsuhiro Goda, Kei Kawada, Yuki Izawa-Ishizawa and Keisuke Ishizawa : Exploration of drugs that affect treatment with anti-VEGF drugs, 30th Congress of the Federation of Asian Pharmaceutical Associations; FAPA2024, Seoul, Oct. 2024.
2.	Takahiro Niimura, Koji Miyata, Kenta Yagi, Fuka Aizawa, Kei Kawada, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa : Evaluation of cardiovascular toxicity profile of ALK inhibitors using adverse event reporting database., ASCPT 2024 Annual Meeting Colorado Springs March 2024, Colorado Springs, Mar. 2024.
3.	Koji Miyata, Yuki Izawa-Ishizawa, Honoka Nishi, Shuto Itokazu, Tatsumi Miyata, Kaito Tsujinaka, Masateru Kondo, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa : Fluoroquinolones attribute aortic diseases through endothelial dysfunction., ASCPT 2024 Annual Meeting, Colorado Springs, Mar. 2024.
4.	Kei Kawada, Ishida Tomoaki, Morisawa Shumpei, Jobu Kohei, Higasi Youichirou, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa : Atractylodes lancea Rhizome-derived Exosome-like Nanoparticles Suppress Lipopolysaccharide-induced Inflammation in Murine Microglial Cells, 81st FIP World Congress of Pharmacy and Pharmaceutical Sciences., Brisbane, Sep. 2023.

Proceeding of Domestic Conference:

1.	Kenta Yagi, Sayaka Imawaka, Mayu Takaoka, Naoki Okamoto, Fuka Aizawa, Takahiro Niimura, Mitsuhiro Goda, Kei Kawada, Yuki Izawa-Ishizawa and Keisuke Ishizawa : Bcr-Abl 阻害剤に対する慢性骨髄性白血病細胞の耐性獲得メカニズムの探索, 第144回日本薬理学会近畿部会, Mar. 2024.
2.	Yuki Izawa-Ishizawa, Koji Miyata, Kaito Tsujinaka, Shuto Itokazu, Tatsumi Miyata, Masateru Kondoh, Takahiro Niimura, Toshihiko Yoshioka, Fuka Aizawa, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa : フルオロキノロン系抗菌薬による大動脈疾患リスクに関する2つの矛盾, 第144回日本薬理学会近畿部会, Mar. 2024.
3.	Fuka Aizawa, Ami Okabayashi, Daishi Moriyama, Kenta Yagi, Takahiro Niimura, Mitsuhiro Goda, Yuki Izawa-Ishizawa, Kei Kawada and Keisuke Ishizawa : HMG-CoA還元酵素阻害剤はGST を介して抗がん剤誘発性機械的刺激応答閾値低下を改善する, 第144回日本薬理学会近畿部会, Mar. 2024.
4.	Tatsumi Miyata, Yuki Izawa-Ishizawa, Koji Miyata, Shuto Itokazu, Kaito Tsujinaka, Himeno Fukuoka, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa : レボフロキサシンの血管炎症への影響, 第268回徳島医学会, Mar. 2024.
5.	Shuto Itokazu, Yuki Izawa-Ishizawa, Koji Miyata, Tatsumi Miyata, Masateru Kondoh, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa : 杜仲葉エキスによる大動脈疾患発症抑制効果の検討, 第268回徳島医学会, Mar. 2024.
6.	福田仁, Takahiro Niimura, Kei Kawada, 石田智滉, 川西裕, 門田知倫, Mitsuhiro Goda, 安藤里英, Keisuke Ishizawa and 上羽哲也 : クラゾセンタンの体液貯留リスク因子の探索 -Japanese Adverse Drug Event Report (JADER)より-, 第41回SAH/スパズム・シンポジウム, Mar. 2024.
7.	Yui Nagao, Chiemi Sato, YAMAKAWA Ayumi, Takaaki Yamamoto, Kei Kawada and Shinji Abe : ビタミンDサプリメントがアレルギー性鼻炎に与える効果の検討―システマティックレビューとメタ解析―, 日本薬学会第144年会(横浜), Mar. 2024.
8.	Koji Miyata, Yuki Izawa-Ishizawa, Honoka Nishi, Shuto Itokazu, Tatsumi Miyata, Kaito Tsujinaka, Masateru Kondoh, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa : フルオロキノロン系抗菌薬に関連した大動脈瘤解離には内皮障害が関与する, 第97回日本薬理学会年会第44回日本臨床薬理学会学術総会, Dec. 2023.
9.	Kei Kawada, 石田智滉, 福田仁, 兵頭勇己, 浜田知幸, 久保亨, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Mitsuhiro Goda and Keisuke Ishizawa : 機械学習解析を用いた心不全治療薬の年齢別有効性の検討―高知急性非代償性心不全レジストリ研究より―, 第97回日本薬理学会年会第44回日本臨床薬理学会学術総会, Dec. 2023.
10.	石田智滉, Kei Kawada, 濵田知幸, 門田亜紀, 森田靖代, 福田仁, 久保亨, 常風興平 and 北岡裕章 : 急性非代償性心不全患者における心臓機能に関連しない因子の生命予後に対する影響, 第33回医療薬学会年会, Nov. 2023.
11.	Kei Kawada, 石田智滉, Mitsuhiro Goda and Keisuke Ishizawa : 基礎研究の力で明らかになる新たな真実:clinical questionの解決に向けて, 第33回医療薬学会年会, Nov. 2023.
12.	杉本祐悟, Mitsuhiro Goda, 石田朋奈, 加納菜々, Masaya Kanda, Toshihiko Yoshioka, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Kei Kawada, Yuki Izawa-Ishizawa and Keisuke Ishizawa : SGLT2阻害薬によるシスプラチン誘発腎障害の抑制効果, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
13.	Kenta Yagi, Takahiro Niimura, Satoshi Sakaguchi, Fuka Aizawa, Kei Kawada, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa : リアルワールドデータの医療への活用に向けて, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
14.	神農麻里奈, 小川敦, 鈴木加奈, 萱野純史, Masaya Kanda, Kaito Tsujinaka, Takashi Bandoh, Ayaka Nitta, 椋田千晶, Fuka Aizawa, Kei Kawada, 櫻田巧, 桐野靖, Mitsuhiro Goda and Keisuke Ishizawa : 処方提案受容率向上を目指した栄養輸液設計ツールの検討, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
15.	岡崎萌水, 石田智滉, 佐川喬也, 丸岡由奈, Kei Kawada, 浜田知幸, 門田亜紀, 森田靖代, 久保亨, 常風興平 and 北岡裕章 : 急性非代償性心不全患者における服薬アドヒアランス不良を予測するスコアの作成―高知急性非代償性心不全レジストリ研究より―, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
16.	西村さとみ, 石田智滉, 赤垣恵太, 森沢惇平, Kei Kawada, 川添哲嗣, 宮村充彦 and 常風興平 : 植物由来Exosome like nanoparticles(ELNs )の医療への応用-生姜由来ELNsの抗神経炎症作用-, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
17.	西田基紀, 石田智滉, 赤垣恵太, 森沢惇平, Kei Kawada, 川添哲嗣, 宮村充彦 and 常風興平 : Zingiber mioga 花穂酢酸エチル抽出エキスの神経炎症抑制作用, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
18.	石田智滉, Kei Kawada, 濱田知幸, 兵頭勇己, 福田仁, 久保亨, 常風興平 and 北岡裕章 : 急性非代償性心不全患者における生命予後に対する身体機能関連因子の影響―高知急性非代償性心不全レジストリ研究より―, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
19.	Wakako Minami, Chiemi Sato, Takaaki Yamamoto, Kei Kawada and Shinji Abe : 電子版お薬手帳の利用推進における問題点の検討―徳島県の薬局薬剤師に対するアンケート調査より―, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
20.	Chisaki Yamaguchi, Chiemi Sato, Yui Nagao, Takaaki Yamamoto, Kei Kawada and Shinji Abe : ベンゾジアゼピン受容体作動薬の服用と認知機能低下の関連性評価 ―システマティックレビューとメタ解析―, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
21.	Takuya Wada, Satoshi Itakura, Aito Yoshida, Takaaki Yamamoto, Kei Kawada, Chiemi Sato, 金子美華, 加藤幸成, Yasuhiko Nishioka and Shinji Abe : がん特異的抗podoplanin抗体chLpMab-23fのMPM胸腔内移植マウスモデルにおける抗腫瘍効果の検討, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(高知), Oct. 2023.
22.	Satoshi Itakura, Takuya Wada, Aito Yoshida, Takaaki Yamamoto, Kei Kawada, Chiemi Sato, 金子美華, 加藤幸成, Yasuhiko Nishioka and Shinji Abe : がん特異的抗podoplanin抗体chLpMab-2及びコアフコース除去抗体chLpMab-2fのin vivoにおける抗腫瘍効果の検討, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(高知), Oct. 2023.
23.	Aito Yoshida, Satoshi Itakura, Takuya Wada, Takaaki Yamamoto, Kei Kawada, Chiemi Sato, 金子美華, 加藤幸成, Yasuhiko Nishioka and Shinji Abe : がん特異的抗podoplanin抗体のコアフコース除去に伴うADCC増強とNK細胞活性化に関する検討, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会(高知), Oct. 2023.
24.	石田智滉, 常風興平, 森沢惇平, Kei Kawada, 白石久, 赤垣恵太, 菅野仁美, 西山光恵 and 宮村充彦 : 配糖体の薬物動態と腸内細菌叢の関係 -経口抗生剤負荷マウスにおけるグリチルリチン酸の体内動態の解析-, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
25.	Kei Kawada, 石田智滉, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa : 植物由来細胞外膜小胞を用いた抗神経炎症治療薬の開発, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
26.	Kei Kawada, 石田智滉, 常風興平, 森沢惇平, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa : 植物由来Exosome-like Nanoparticles (ELNs)の医療への応用 -蒼朮由来ELNsによる抗神経炎症作用の検討-, 第143回日本薬理学会近畿部会, Jun. 2023.
27.	岡崎萌水, 柳澤成佳, 加賀屋陽子, 岡崎雅史, 八木祐助, 石田智滉, 藤田博子, Kei Kawada, 常風興平 and 宮村充彦 : 医薬品副作用データベース(JADER)を用いたプロトンポンプ阻害薬による血小板減少症に関する網羅的解析, 第34回日本臨床モニター学会総, Apr. 2023.
28.	八木祐助, 石田智滉, 西田基紀, Kei Kawada, 常風興平, 荒川悠, 山岸由佳 and 宮村充彦 : Spontaneous Reporting Systemを用いた医薬品の安全性の評価ー医薬品副作用データベース(JADER)を用いたLinezolidの安全性に関する網羅的解析ー, 日本薬学会第143年会, Mar. 2023.
29.	赤垣恵太, 田村尚久, 石田智滉, 佐川喬也, 白石久, 加賀屋陽子, Kei Kawada, 門田亜紀, 吉岡三郎, 常風興平 and 宮村充彦 : 重症心身障害児等におけるセレン欠乏症患者のQOL向上に向けた取り組みー新規セレン内用速報錠の開発ー, 日本薬学会第143年会, Mar. 2023.
30.	常風興平, Kei Kawada, 石田智滉, 田村尚久, 西田基紀, 西村さとみ, 藤田博子, 川添哲嗣, 吉岡三郎 and 宮村充彦 : 植物由来Exosome like nanoparticles (ELNs) の医療への応用ーニラ (Allium tuberosum) 由来ELNsの抗神経炎症作用ー, 日本薬学会第143年会, Mar. 2023.
31.	赤垣恵太, 田村尚久, 石田智滉, 門田亜紀, 白石久, 加賀屋陽子, Kei Kawada, 門田亜紀, 吉岡三郎, 常風興平 and 宮村充彦 : 重症心身障害児等におけるセレン欠乏症患者のQOL向上に向けた取り組み -新規セレン内用速報錠の開発-, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
32.	丸岡由奈, 白石久, 西村さとみ, 森沢惇平, 岡﨑雅史, 森田咲美, 清水倫子, 原瑠美, 柳澤成佳彦, 岡崎萌水, 野村政孝, Kei Kawada, 森田靖代, 常風興平, 門田亜紀 and 宮村充彦 : 病院経営に対する薬剤部の取り組み -免疫チェックポイント阻害薬が医薬品購入金額に与える影響-, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
33.	Kei Kawada, 石田智滉, 森沢惇平, 常風興平, 藤田博子, 川添哲嗣彦, 吉岡三郎 and 宮村充彦 : 植物由来 Exosome like nanoparticles (ELNs) の医療への応用 -蒼朮由来ELNsによる抗神経炎症作用の検討-, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
34.	田村尚久, 石田智滉, Kei Kawada, 常風興平 and 森沢惇平 : Spontaneous Reporting Systemを用いた医薬品の安全性及び有効性の評価 -JADERを用いた抗がん剤による低ナトリウム血症の解析-, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
35.	杉本翔平, 石田智滉, Kei Kawada, 常風興平, 森沢惇平, 吉岡三郎, 宮村充彦, 宅間大祐 and 濱田篤秀 : Spontaneous Reporting Systemを用いた医薬品の安全性及び有効性の評価 -JADERを用いたVEGF阻害薬による中枢神経虚血の解析-, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
36.	八木祐助, 岡﨑萌水, 柳澤成佳, 山口真夏, Kei Kawada, 荒川悠, 山岸由佳 and 宮村充彦 : 誤嚥性肺炎患者におけるprotocol-based pharmacotherapy management の実践と評価, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
37.	石田智滉, 森沢惇平, Kei Kawada, 常風興平, 吉岡三郎 and 宮村充彦 : 蒼朮由来Exosome like nanoparticlesによるメラニン産生抑制効果の検討, 日本生薬学会第68回年会, Sep. 2022.
38.	Kei Kawada, 石田智滉, 常風興平, 森沢惇平, 田村尚久, 藤田博子, 西田基紀, 川添哲嗣, 吉岡三郎 and 宮村充彦 : 抑肝散における術後せん妄に対する有用性と有効生薬に関する検討, 日本生薬学会第68回年会, Sep. 2022.
39.	赤垣恵太, 石田智滉, 常風興平, Kei Kawada, 川添哲嗣, 森沢惇平, 田村尚久 and 宮村充彦 : Spontaneous Reporting Systemを用いた医薬品の安全性及び有効性の評価 JADERを用いた防風通聖散服用者における薬剤性肝障害の解析, 日本薬学会年会要旨集 142年会, Mar. 2022.
40.	森沢惇平, 石田智滉, Kei Kawada, 常風興平, 田村尚久, 中村優李, 政平訓貴, 川西裕, 福田仁, 上羽哲也, 山本新九郎, 井上啓史 and 宮村充彦 : 悪性神経膠腫の開頭脳腫瘍摘出術における光線力学的診断用剤5-Amino levulinic acid製剤と血圧低下との関連, 日本薬学会年会要旨集 142年会, Mar. 2022.
41.	丸岡由奈, Kei Kawada, 石田智滉, 常風興平, 森沢惇平, 川添哲嗣, 田村尚久, 西村さとみ, 西田基紀, 藤田博子, 吉岡三郎, 久保亨, 北岡裕章 and 宮村充彦 : 急性非代償性心不全患者における服薬アドヒアランスと社会支援との関連, 日本薬学会年会要旨集 142年会, Mar. 2022.
42.	Kei Kawada : 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 漢方製剤の臨床応用に対する科学的検証 -せん妄病態モデルマウスに対する抑肝散投与の影響-, Oct. 2021.
43.	加賀屋陽子, 門田亜紀, 赤垣恵太, 田村尚久, 石田智滉, Kei Kawada, 船戸裕樹, 片岡晃一, 白石久, 吉岡三郎, 常風興平 and 宮村充彦 : 重症心身障害児等におけるセレン欠乏症患者のQOL向上に向けた取り組み -新規セレン内用速報錠の開発-, 第48回日本小児臨床薬理学会, Oct. 2021.
44.	Kei Kawada, 石田智滉, 森沢惇平, 川添哲嗣, 岡本茉奈実, 藤田博子, 常風興平, 森田靖代, 宮村充彦, 久保亨, 北岡裕章, 福田仁 and 太田剛史 : 心不全患者におけるせん妄発症リスク因子の解析抗不安作用ベンゾジアゼピン系薬剤との関連, 日本循環器学会学術集会抄録集 85回, Mar. 2021.
45.	川添哲嗣, 石田智滉, Kei Kawada, 西田基紀, 森沢惇平, 常風興平, 門田亜紀, 森田靖代 and 宮村充彦 : 蓄積された医療情報を用いた医薬品の安全性及び有効性の評価(第2報) 有害事象自発報告データベースを用いたサイクリン依存キナーゼ4/6阻害薬に関する有害事象の評価, 日本薬学会年会要旨集 141年会, Mar. 2021.
46.	森田靖代, 石田智滉, 森沢惇平, Ou Yanglan, 川添哲嗣, Kei Kawada, 藤田博子, 門田亜紀, 常風興平 and 宮村充彦 : フレイル予防に有用な天然資源由来物質の探索(第10報) 十全大補湯エキスによる加齢性骨格筋萎縮予防効果の検討, 日本薬学会年会要旨集 141年会, Mar. 2021.
47.	Yanglan Ou, 石田智滉, 石田七生, 川添哲嗣, Kei Kawada, 森沢惇平, 飯塚美知郎, 藤田博子, 常風興平, 森田靖代 and 宮村充彦 : フレイル予防に有用な天然資源由来物質の探索(第8報) -糖尿病性肥満マウスに対する柴胡桂枝乾姜湯エキスの骨格筋萎縮予防効果-, 第59日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Dec. 2020.
48.	森田靖代, 石田智滉, 森沢惇平, Yanglan Ou, 川添哲嗣, Kei Kawada, 藤田博子, 門田亜紀, 常風興平 and 宮村充彦 : フレイル予防に有用な天然資源由来物質の探索(第9報)-老化促進マウスを用いた十全大補湯エキスの骨格筋萎縮予防効果の検討-, 第59日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Dec. 2020.
49.	石田智滉, 常風興平, 森沢惇平, 白石久, 藤田博子, Kei Kawada, 菅野仁美, 西山光恵, 森田靖代, 宮村充彦 and 花﨑和弘 : 配糖体の薬物動態と腸内細菌叢の関係性-経口抗生剤負荷マウスにおけるグリチルリチン酸の体内動態の解析-, 第37回和漢医薬学会学術大会, Aug. 2020.
50.	下元理恵, 久保亨, 片田秦椰, 津村早保, 宮地昌文, 前田貴之, Kei Kawada, 山崎真由美, 高原優, 長山真紀, 馬場裕一, 濱田知幸, 山中福子, 眞茅みゆき and 北岡裕章 : 高知県における在宅心不全管理についての実態提供されている医療情報の満足度と提供してほしい医療情報, 日本循環器学会学術集会抄録集 84回, Jul. 2020.
51.	山中福子, 下元理恵, 久保亨, 片田秦椰, 津村早保, 宮地昌文, 前田貴之, Kei Kawada, 山崎真由美, 高原優, 長山真紀, 馬場裕一, 濱田知幸, 眞茅みゆき and 北岡裕章 : 高知県における在宅心不全管理についての実態疾病管理における困難経験, 日本循環器学会学術集会抄録集 84回, Jul. 2020.
52.	西田基紀彦, Kei Kawada, 柳澤成佳, 川添哲嗣, 船戸裕樹, 上田真由美, 門田亜紀, 常風興平, 森田靖代 and 宮村充彦 : ICTを活用した医薬品適正使用サイクルの推進(第1報)-処方設計支援システム構築とその有用性-, 第30回日本医療薬学会, Nov. 2019.
53.	石田智滉, Kei Kawada, 森沢惇平, 常風興平, 森田靖代 and 宮村充彦 : 蓄積された医療情報を用いた医薬品の安全性及び有効性の評価(第1報)-JADERを用いた抑肝散服用者における偽アルドステロン症発症に対するリスク因子の検討-, 第30回日本医療薬学会, Nov. 2019.
54.	Kei Kawada : 救急・集中治療における薬剤師の医薬品安全管理への取り組み~病棟薬剤業務実施加算に繋がったエビデンスの創出~, 医療薬学フォーラム27th, Nov. 2019.
55.	Kei Kawada : いつもの業務から始まる臨床研究~薬剤師のあらたな役割のために~, 日本医療薬学会年会 29, Nov. 2019.
56.	斎藤秀明, 氏原晶世, Kei Kawada, 斎藤照子, 有澤里彩, 西岡明人 and 森田荘二郎 : 診療情報管理士のクリニカルパスを通じた介入による薬物療法の適正使用の推進, 日本診療情報管理学会学術大会45回, Aug. 2019.
57.	小笠原瑞穂, Kei Kawada, 太田剛史, 山崎好恵, 津野文香, 藤澤康代, 公文登代, 段松雅弘, 今井利 and 田中聡 : 血液がん化学療法患者における機能性便秘に対する適切な緩下剤選択, 第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2018.

Et cetera, Workshop:

1.	Kei Kawada, 小松仁美, 上田真由美, 西田基紀 and 宮村充彦 : 医薬品適正使用における処方チェックシステムの有用性と併用禁忌医薬品に対する取り組み, 高知県薬剤師会報, 2020.
2.	石本倫子, Kei Kawada, 太田剛史, 町田拓哉 and 岡田由香里 : 検査技師から能動的な情報提供による洗浄血小板の使用推進, 高知医療センター医学雑誌, Vol.9, No.1-2, 69-71, Dec. 2019.
3.	石本倫子, Kei Kawada, 太田剛史, 町田拓哉, 武政雄大, 筒井敬子 and 岡田由香里 : 検査技師から能動的な情報提供による洗浄血小板の使用推進, こうち : 一般社団法人高知県臨床検査技師会会誌, Vol.48, No.2, 39-43, 2019. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520575528636053888 (CiNii: 1520575528636053888)

Patent:

1.	Kei Kawada, 宮村充彦, 常風興平 and 石田智滉 : 神経変性疾患抑制剤, P 2022163020 (Oct. 2022), P2024056263 (Apr. 2024), P2024056263 (Apr. 2024).
2.	Kei Kawada, 宮村充彦, 常風興平 and 石田智滉 : 薬物輸送担体, P 2022163039 (Oct. 2022), P2024056273 (Apr. 2024), P2024056273 (Apr. 2024).
3.	Kei Kawada, 宮村充彦, 常風興平 and 石田智滉 : 神経変性疾患抑制剤, P 2022163069 (Oct. 2022), P2024056288 (Apr. 2024), P2024056288 (Apr. 2024).

Assistant Professor : Kawada, Kei

Research

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Patent: